Company news
Sarepta Therapeutics, Inc. news in 2023
Sarepta Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
December 21, 2023
Sarepta Therapeutics to Present at the UBS Biopharma Conference
November 1, 2023
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
October 31, 2023
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
October 29, 2023
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
October 24, 2023
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
September 6, 2023
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 4, 2023
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
August 29, 2023
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
August 1, 2023
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
July 25, 2023
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
July 4, 2023
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
July 2, 2023
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
June 21, 2023
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
May 23, 2023
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
May 11, 2023
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
May 1, 2023
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
April 24, 2023
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
April 9, 2023
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
March 15, 2023
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
February 27, 2023
Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
February 27, 2023
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
February 20, 2023
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
February 16, 2023
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
January 8, 2023
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
January 4, 2023
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Calls in 2023
- Sarepta Therapeutics (NASDAQ:SRPT) Q3 2023 Earnings Call
Nov 1, 2023
Transcript - Sarepta Therapeutics (NASDAQ:SRPT) Q2 2023 Earnings Call
Aug 2, 2023
Transcript - Sarepta Therapeutics (NASDAQ:SRPT) Q1 2023 Earnings Call
May 2, 2023
Transcript - Sarepta Therapeutics (NASDAQ:SRPT) Q4 2022 Earnings Call
Feb 28, 2023
Transcript
Decks in 2023
- Corporate Update (June 2023)
Corporate update · 18 slides · Jun 22, 2023
- JPMorgan Healthcare Conference 2023
Conference · 20 slides · Jan 9, 2023